Thermo Fisher Scientific Inc.
TMO · NYSE
9/27/2025 | 6/28/2025 | 3/29/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $175,483 | $154,330 | $189,060 | $199,168 |
| - Cash | $1,982 | $4,579 | $4,134 | $4,009 |
| + Debt | $35,680 | $35,229 | $34,189 | $32,775 |
| Enterprise Value | $209,181 | $184,980 | $219,115 | $227,934 |
| Revenue | $11,122 | $10,855 | $10,364 | $11,395 |
| % Growth | 2.5% | 4.7% | -9% | – |
| Gross Profit | $4,652 | $4,048 | $4,245 | $4,467 |
| % Margin | 41.8% | 37.3% | 41% | 39.2% |
| EBITDA | $2,838 | $2,798 | $2,628 | $3,068 |
| % Margin | 25.5% | 25.8% | 25.4% | 26.9% |
| Net Income | $1,616 | $1,617 | $1,507 | $1,830 |
| % Margin | 14.5% | 14.9% | 14.5% | 16.1% |
| EPS Diluted | 4.27 | 4.28 | 3.98 | 4.78 |
| % Growth | -0.2% | 7.5% | -16.7% | – |
| Operating Cash Flow | $2,239 | $1,399 | $723 | $3,290 |
| Capital Expenditures | -$404 | -$294 | -$362 | -$480 |
| Free Cash Flow | $1,835 | $1,105 | $361 | $2,810 |